Parsaclisib|cas 1426698-88-5|DC Chemicals

Cas No.:	1426698-88-5
Chemical Name:	Parsaclisib
Synonyms:	Parsaclisib;INCB050465;Parsaclisib free base;OS7097575K;(4R)-4-{3-[(1S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one;(4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one;Parsaclisib [INN];Parsaclisib [USAN];Parsaclisib (USAN/INN);Parsaclisib [USAN:INN];INCB050465 free base
SMILES:	ClC1C=C(C(=C(C=1F)[C@H]1CC(NC1)=O)OCC)[C@H](C)N1C2C(=C(N)N=CN=2)C(C)=N1
Formula:	C₂₀H₂₂ClFN₆O₂
M.Wt:	432.879086017609
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Parsaclisib is a potent and selective PI3Kδ inhibitor, with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases.

In Vitro:

Parsaclisib (INCB050465) is a potent and selective PI3Kδ with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases. Parsaclisib displays significant activity with IC50 values ranging from 0.2 to 2 nM in B and T cell proliferation aaasys. Parsaclisib inhibits proliferation of several DLBCL and MCL cell lines in vitro (EC50 < 10 nM)[1].

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC74260	cyclo-CRVLIR	cyclo-CRVLIR is a cyclic peptide that binds selectively to p110α RAS binding domain (p110α-RBD) with ITC Kd of 3 uM, blocks p110α/RAS interaction in vitro and KRAS cancer cell lines.
DC72848	Leniolisib phosphate	Leniolisib (CDZ173) phosphate is a potent and selective PI3Kδ inhibitor. Leniolisib phosphate has the potential for immunodeficiency disorders treatment.
DC47383	GSK251	GSK251 is a highly potent, highly selective, orally bioavailable inhibitor of PI3Kδ with a novel binding mode.
DC42549	Parsaclisib hydrochloride	Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies.
DC42415	IHMT-PI3Kδ-372	IHMT-PI3Kδ-372 is a potent and selective PI3Kδ with an IC50 of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56∼83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research.
DC42414	Zandelisib	Zandelisib is a phosphatidylinositol 3-kinase (PI3K) extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC50 of 3.5 nM. Zandelisib functions as an antineoplastic.
DC40777	MSC2360844(IOA-244 /roginolisib)	MSC2360844 is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. MSC2360844 shows highly selective against a panel of 278 additional kinases.
DC28978	Copanlisib dihydrochloride (BAY 80-6946)	Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has
DC11906	Parsaclisib	Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies.
DC1077	ZSTK474	ZSTK474 is a potent pan-class I PI3K inhibitor with IC50 of 37 nM.